Summary:
- Nuclidium, a Swiss radiopharmaceutical company, secured €84M in Series B funding.
- The funding will be used to advance its Copper-61/Copper-67 theranostic pipeline for cancer treatment.
- The company is known for its innovative copper-based radiopharmaceuticals for diagnosing and treating cancer.
—
In a recent development, Nuclidium, a clinical-stage radiopharmaceutical company based in Basel, Switzerland, successfully closed a Series B funding round, raising an impressive €84M. The funding round was co-led by prominent investors such as Angelini Ventures, Kurma Growth Opportunities Fund, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), along with participation from DeepTech, Climate Fonds, Bayern Kapital, Eurazeo, Vives Partners, NRW.BANK, and HighLight Capital, as well as existing investors.
The primary objective of this funding injection is to expedite the clinical development of Nuclidium’s Copper-61/Copper-67 theranostic pipeline across various oncology indications. Additionally, the company plans to enhance its production and manufacturing capabilities through the establishment of a global production network. This strategic move aims to scale up the delivery of innovative and clinically superior theranostic solutions to cancer patients worldwide.
Nuclidium AG, under the leadership of CEO Leila Jaafar-Thiel, is at the forefront of pioneering new copper-based radiopharmaceuticals for cancer diagnosis and treatment. By leveraging copper isotopes, specifically Copper-61 for diagnostics and Copper-67 for therapeutics, Nuclidium is revolutionizing the field of radiotheranostics. The company’s operations in Switzerland and Germany integrate expertise in chemistry, clinical research, and strategic manufacturing to develop accessible and scalable solutions for cancer patients.
Regina Hodits, PhD, Managing Director at Angelini Ventures, is set to join Nuclidium’s Board of Directors, bringing valuable insights and guidance to the company’s strategic direction. With a commitment to innovation and patient-centric care, Nuclidium is poised to make significant strides in the advancement of radiopharmaceuticals for cancer treatment.
This latest funding milestone underscores Nuclidium’s dedication to revolutionizing cancer care through cutting-edge radiopharmaceutical solutions. As the company continues to expand its reach and capabilities, the future looks promising for the development of advanced theranostic options for cancer patients globally.
